language-icon Old Web
English
Sign In
Acemap > Paper > Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1 or NTRK plus Advanced Solid Tumors

Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1 or NTRK plus Advanced Solid Tumors

2021 
Keywords:
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []
    logo
    • CCF Conference Analysis
    • Map Galaxy
    • What's New
    © Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.